LIMS2

Across TCGA pan-cancer cohorts, LIMS2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LIMS2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LIMS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LIMS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where LIMS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.670	0.996	<.001	34	view →
HNSC	DFS	Quartile	III,IV	0.916	0.642	.006	13	view →
UCEC	OS	Tertile	III,IV	0.282	1.000	.022	8	view →
PDAC	OS	Quartile	All	0.688	0.438	.006	6	view →
OV	DFS	Tertile	All	0.701	1.000	.049	4	view →
LSCC	OS	Median	II,III,IV	0.904	1.000	.019	3	view →
CCRCC	DFS	Quartile	III,IV	0.789	0.323	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LIMS2–LUAD (DFS)

Open the LUAD breakdown →